Early induction of docetaxel for castration resistance prostate cancer

Early induction of docetaxel for castration resistance prostate cancer - PC-DOC

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004072

Enrollment

Registered

2010-08-19

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

early induction with docetaxel in the stage of the PSA biochemical failure with combined androgen blockade the cases who reject to receive the early induction of docetaxel who entry in the control gro

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)Diagnosed prostate cancer under pathological examination 2)high risk (PSA over 20 or over Gleason score 8 or over T3staged), not permitted local radiotherapy or operation 3)initial hormonal therapy with combined androgen blockage adapted and PSA biochemical failure is decided without the PSA nadir lower than 0.2ng/dl , serum testosterone lower than 50 ng/ml) 4)age under 80 5)performance status 0 or 1 6)normal range of labo data 7)consensus for informed consent 8)the cases who reject to receive docetaxel will entry in the control group

Exclusion criteria

Exclusion criteria: 1)active infection 2)fever over 38 cent degree 3)allergy with docetaxel or steroid 4)physician deny the entry

Design outcomes

Primary

Measure	Time frame
Response of PSA level	—

Secondary

Measure	Time frame
1)safeness 2)progression free survival 3) overall survival	—

Countries

Japan

Contacts

Public ContactKouhei Nishikawa

Mie University Graduate School of Medicine, Nephro-Urologic Surgery

n-soga@clin.medic.mie-u.ac.jp059-232-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026